biopharmaceutical

The TriLink BioTechnologies

For more than 20 years, TriLink has led the market in producing high-quality oligonucleotides for research, diagnostics, medicines, and OEM. In quantities up to several grams, we provide a large variety of DNA, RNA, modified, and custom oligonucleotides.

The TriLink BioTechnologies

What we do?

Best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, NTPs, and mRNA capping analogs is TriLink BioTechnologies, a division of Maravai LifeSciences. TriLink provides firms working on therapeutic, vaccine, diagnostic, and biopharmaceutical breakthroughs with scale-up knowledge as well as distinctive mRNA, oligonucleotide, and plasmid manufacturing capabilities. TriLink is a vital source of modified nucleic acids for biopharmaceutical firms, and it also works with them as a CDMO partner to help them transition from preclinical research to clinical trials. By eliminating extra enzymatic steps, TriLink’s patented CleanCap® mRNA co-transcriptional capping technology streamlines the production of mRNA and produces higher yields than conventional co-transcriptional capping techniques. With scale-up and technology transfer experience, TriLink’s CDMO services provide a variety of manufacturing grade goods, from discovery-grade (RUO) to complete GMP-grade.

25 years as a pioneer in the nucleic acid synthesis business

The TriLink BioTechnologies

1996

California’s San Diego was founded in May. TriLink moves into its first commercial lab facility before year’s end, starts delivering oligonucleotides, and hires its first staff members.

1997

Obtains a license to produce radioactive substances. TriLink swiftly establishes itself as a market pioneer and among the few businesses in the world to effectively produce radio-labeled oligos.

1998

David Broide et al.’s article, Immunostimulatory DNA sequences suppress IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice, is the first customer-written publication to mention TriLink products.

1999

becomes nucleoside triphosphates as it grows. cofounds Solulink®, a business that specializes in distinctive bioconjugation chemistries. First lab becomes too small, so it moves to Nancy Ridge. The first article published under the TriLink corporation brand.

2022

 Company expands to a 40,000 square foot structure that functioned as the corporate headquarters as it continues to see exceptional growth.

2005

receives the first of four SBIR funds for the development of enhanced hot-start PCR using chemically modified primers and NTPs, the core of the CleanAmp® product line.

2006

A first alliance agreement with a significant therapeutic oligo CMO is sparked by proven pre-clinical oligo manufacturing, allowing clients to swiftly move from research and development to clinical trials.

2011

Utilizing knowledge of complex nucleic acids, IVT long RNA and mRNA manufacturing is started for application in pharmaceutical research and development. The CleanAmp® first patent gets approved.

2014

receives certification for ISO 9001. opens a cutting-edge cGMP production facility and diversifies into therapeutic mRNA and oligonucleotides. secures a deal with Battelle for the creation of an Ebola vaccine. Patents granted for the exclusive CleanTag® technology.

2015

More than 6,000 publications in 2015 cited TriLink products. extends the options for mRNA purification and adds gram scale mRNA synthesis. the introduction of CleanTag® Small RNA Library Prep kits. co-founds ETAGEN with Tod Woolf, a business that specializes in gene editing technology.

The TriLink BioTechnologies

2016

Maravai LifeSciences made a strategic investment.

2017

Launched in 2017, CleanCap® is a proprietary mRNA capping technique that significantly outperforms earlier technologies.

2018

Obtains ISO 9001:2015 certification .

2019

TriLink & Maravai will relocate to a new global headquarters in 2019. 105,000 square feet of facility space and 50,000 square feet of specialized production space, including 5 cGMP suites, are available.

2020

Two patents on CleanCap® technology have been issued. Capped trinucleotide primers and capped tetranucleotide primers are covered by the patents, however they are not restricted to any specific sequences.

2021

The addition of plasmid manufacturing to the offerings.

2021 TriLink BioTechnologies acquires a European Patent for its CleanCap® technology, expanding its intellectual property portfolio.

2022

2022 MyChem, a leader in proprietary ultra-pure nucleotides, is acquired by Maravai LifeScience.

How many people work for TriLink?

The corporate headquarters of TriLink BioTechnologies are in 10770 Wateridge Cir Ste 200, San Diego, California, 92121, and they employ 247 people.

What is TriLink Biotechnology’s revenue?

The $17.5 million revenue of TriLink BioTech.

Plasmid production

The TriLink BioTechnologies

ReciBioPharm provides a complete plasmid synthesis solution that gives your project the greatest possible start. When you pick our pDNA services, you can count on dependability thanks to our considerable experience and wide-ranging offering in plasmid manufacture. With the help of in-house knowledge, pDNA manufacturing may be flexible and innovative to tailor and expedite timetables, cut costs, and retain the highest quality. 

services for plasmids

The TriLink BioTechnologies

ReciBioPharm is your go-to supplier for GMP plasmid made in Grade C clean rooms under the strict supervision of quality assurance. We can satisfy your needs in a wide range of cell and gene therapy, viral vector, and mRNA applications thanks to our broad plasmid capabilities, which cover both upstream and downstream procedures.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *